Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03435562 · ClinicalTrials.gov registry record · NA

Assessment of Two New Electronic Cigarettes in Cigarette Smokers

A NA study, sponsored by Virginia Commonwealth University.

Completed
Registry status
NA
Development phase
22
Enrollment target

NCT03435562: Completed NA study, sponsored by Virginia Commonwealth University.

NCT03435562 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03435562, a NA study, has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target

Study Summary

The purpose of this study is to determine differences in nicotine delivery, user behavior, subjective effects, and physiological effects, when cigarette smokers use an two new electronic cigarette devices (JUUL and IQOS) relative to their using their own brand of cigarettes.

Primary Outcome

Change in plasma nicotine level

Interventions

  • OTHER JUUL electronic cigarette
  • OTHER IQOS electronic cigarette
  • OTHER Own Brand cigarette

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2018-03-03
Est. Completion 2019-08-16
Phase NA
Virginia Commonwealth University

558 total trials

What the finished NCT03435562 record still lists

NCT03435562 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 3 interventions - of which JUUL electronic cigarette is the first listed.

NCT03435562 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03435562 about?

NCT03435562 is a clinical study titled "Assessment of Two New Electronic Cigarettes in Cigarette Smokers". The purpose of this study is to determine differences in nicotine delivery, user behavior, subjective effects, and physiological effects, when cigarette smokers use an two new electronic cigarette devices (JUUL and IQOS) relative to their using their own brand of cigarettes.

What is the current status of trial NCT03435562?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2018-03-03. Estimated completion is 2019-08-16.

What interventions are being tested in trial NCT03435562?

The interventions under investigation include: JUUL electronic cigarette (OTHER), IQOS electronic cigarette (OTHER), Own Brand cigarette (OTHER).

Who is sponsoring clinical trial NCT03435562?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03435562's enrollment target sits among peer trials

22 1756th of 2000 higher than 239 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03435562, the US trial registry maintained by the National Library of Medicine. NCT03435562 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.